




Success

From lab to market 2025.

Introducing one of the world's largest development pipelines for Advanced Therapy Medicinal Products (ATMP).



Commercialising
Technology



Introducing one of the world's largest ATMP pipelines

University College London (UCL) is at the heart of a world-leading integrated ecosystem of research, innovation, clinical trialling and commercialisation for advanced therapies.

In addition to **world-class researchers**, front line practitioners and trialling facilities at UCL's leading partner hospitals, this ecosystem is supported by UCL's Translational Research Office (TRO), Therapeutic Innovation Networks (TINs) and UCL's commercialisation operation UCL Business (UCLB).

The result of this connected community is an unrivalled advanced product development pipeline, with **over 50 projects** in discovery, **34 in preclinical/IND** enabling studies, **34 currently in Phase I/II** clinical trials; **1 in Phase III** clinical trials and two globally important treatments already licensed in the U.S. and/or EU – Roctavian™ for haemophilia and AUCATZYL® for an aggressive blood cancer.

Taken together, this represents one of the world's highest quality research, development, and commercialisation operations, optimising the successful journey of ground-breaking new advanced therapies from lab to patients and market.



Publicly funded academic research compliments our licensing activities and commercial spinout creation

The scale of UCL's support for ATMP development collectively de-risks the pipeline thereby reducing investment risk. This maximises successful commercialisation and is a result of robust financial support by both public and private investment.

Our extensive portfolio of publicly funded projects, along with **UCL and UCLB's** Proof of Concept funding schemes supports early and mid-stage academic research, ensuring our development pipeline is second to none.

The current active portfolio has, **over £66M** of public funding invested in Phase I/II trials and preclinical stage projects, whilst more than 50 projects are in discovery phase, supported by smaller grants.

Extensive pipeline de-risked through significant peer reviewed public funding investment - opportunity to partner. Portfolio information accurate as of December 2024.



Coordinated support leads to successful commercialisation

Our commercial portfolio maps onto UCL's key areas of clinical expertise in Rare Diseases, Ophthalmology Haematology/Oncology, Neurology and Immunology.

We work with commercial partners either by forming spinout business or licensing technologies through UCLB, attracting external/commercial funding to take promising therapeutics through clinical trials to launch.


UCL, UCLB and our hospital partners' extensive professional support – from science-trained business managers, translational research experts and clinical facilities and units – supports this process every step of the way, helping to de-risk projects and maximise venture capital investment.



Extensive professional support and know-how has de-risked projects to attract significant VC investment. Portfolio information accurate as of December 2024.

Commercial ATMP Portfolio

VC/Company Funding




Scale and collaboration to de-risk clinical delivery

Close to 50% of the UK's entire ATMP academically sponsored clinical trials and **over 40%** of all UK's commercial sponsored ATMP trials are conducted via UCL partner hospitals.


Our network of clinical trial centres and specialist medical facilities provide the infrastructure to deliver trials at **scale and at pace**, while our close links with research centres across the world enables effective co-ordination across multiple territories.

UK Academic Sponsored Trials



UCL sponsors 49% of the UK's academic sponsored trials

Industry/Non UK Sponsored Trials



UCL hospital partners are sites for 45% of the UK's commercial sponsored trials

Data Source: Cell and Gene Therapy Catapult ATMP Clinical Trials Database 2024.

Developing the talent pipeline to advance ATMP innovation

UCL offers specialised courses and training programmes to develop a strong talent pipeline, driving innovation and commercial success in the ATMP sector while supporting the industry's growth.

Manufacture and Commercialisation of Stem Cell and Gene Therapies MSc

London, UCL East

Enquiries:
biochem.cgt.queries@ucl.ac.uk



Cell, Gene and Novel Therapies MSc

London, Bloomsbury

Enquiries:
cgt@ucl.ac.uk



Cell and Gene Therapy Bioprocessing (MBI Training, Bioprocess Industries) UCL short course

UCL Department of Biochemical Engineering

Enquiries:
mbi-training@ucl.ac.uk



UCL Translational Research Training – 'ACCELERATE potential' UCL open-access short course

Online

Enquires:
tins@ucl.ac.uk



Talk to us



For information about translational research and industry-academia collaborations, speak to the TRO - Dr Jane Kinghorn, Director, j.kinghorn@ucl.ac.uk



For information about commercialisation, speak to UCLB - Dr Rick Fagan, r.fagan@uclb.com



Join TINS
Scan to enrol as a member of the UCL Therapeutic Innovation Networks (TINS) and receive news and event invitations about therapeutic innovations at UCL. tins@ucl.ac.uk

